Your browser doesn't support javascript.
loading
Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection.
Kotake, Takeshi; Satake, Hironaga; Okita, Yoshihiro; Hatachi, Yukimasa; Hamada, Mamiko; Omiya, Masatomo; Yasui, Hisateru; Hashida, Toru; Kaihara, Satoshi; Inokuma, Tetsuro; Tsuji, Akihito.
Afiliação
  • Kotake T; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Satake H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Okita Y; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
  • Hatachi Y; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Hamada M; Department of Nursing, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Omiya M; Clinical & Translational Research Center, Kobe University Hospital, Kobe, Japan.
  • Yasui H; Department of Medical Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Hashida T; Department of Pharmacy, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Kaihara S; Department of General and Transplant Surgery, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Inokuma T; Department of Gastroenterology, Kobe City Medical Center General Hospital, Kobe, Japan.
  • Tsuji A; Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan.
Asia Pac J Clin Oncol ; 15(1): 63-68, 2019 Feb.
Article em En | MEDLINE | ID: mdl-29984542
BACKGROUND: Reports of hepatitis B virus (HBV) reactivation in solid tumors are very limited, and their frequencies and risk factors were previously unknown. AIM: To evaluate the prevalence and risk factors of HBV reactivation in patients with solid tumors with resolved HBV infection. METHODS: All 1088 patients with solid tumors were assessed for eligibility; 251 patients had resolved HBV infection (negative for HBs antigen and positive for anti-HBc antibody and/or positive for anti-HBs antibody), and HBV-DNA was assessed for 243 of these patients in whom we analyzed the prevalence of HBV reactivation. Risk factors for HBV reactivation were exploratorily evaluated by analysis of a case-control study. RESULTS: The prevalence of HBV-DNA reactivation was 2.1% (95% confidence interval [CI], 0.3-3.9%). We did not observe any exacerbation of HBV-DNA by early intervention. A low anti-HBs antibody titer (<10.0 mIU/mL) and high average daily dexamethasone dose (>1.0 mg/day) were high risk factors, with odds ratios of 5.94 (95% CI, 1.15-30.6, P = 0.03) and 8.69 (95% CI, 1.27-58.8, P = 0.02), respectively. CONCLUSION: HBV reactivation in solid tumor patients was relatively rare. Therefore, risk factors that can identify targets for HBV screening must be determined in future studies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Viral / Vírus da Hepatite B / Hepatite B / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Ativação Viral / Vírus da Hepatite B / Hepatite B / Neoplasias Idioma: En Ano de publicação: 2019 Tipo de documento: Article